Tung, Ying-ChangYing-ChangTungLin, Chia-PinChia-PinLinHsiao, Fu-ChihFu-ChihHsiaoHo, Chien-TeChien-TeHoTzyy-Jer, HsuHsuTzyy-JerChu, You-ChiaYou-ChiaChuWEN-JONE CHENChu, Pao-HsienPao-HsienChu2022-08-052022-08-0520221524-6175https://scholars.lib.ntu.edu.tw/handle/123456789/616188This retrospective multi-institutional database analysis aimed to evaluate the blood-pressure-lowering efficacy and clinical outcomes of a generic versus brand-name nifedipine for hypertension management. A total of 12 693 patients who were prescribed a generic or brand-name nifedipine between January 1, 2011, and December 31, 2018, were identified from the Chang Gung Research Database of Chang Gung Memorial Hospitals, Taiwan. Among them, 2112 (21.4%) were prescribed generic nifedipine. After propensity score matching, both the generic and brand-name groups consisted of 2102 patients. At a mean follow-up of 3 years, the changes in office systolic (p for interaction = .791) and diastolic blood pressure (p for interaction = .689) did not differ significantly between the patients who received the generic and the brand-name nifedipine. There was no significant difference between the two study groups regarding the composite of all-cause mortality, acute myocardial infarction, stroke, coronary revascularization, or hospitalization for heart failure (hazard ratio 0.98, 95% confidence interval 0.85-1.13; p = .774). In conclusion, the generic nifedipine was comparable to its brand-name counterpart regarding office blood pressure reduction and the composite cardiovascular outcome for the treatment of patients with hypertension.enblood pressure; generic drug; nifedipine; outcome[SDGs]SDG3journal article10.1111/jch.14478353842512-s2.0-85127517806WOS:000778519800001https://scholars.lib.ntu.edu.tw/handle/123456789/604379